Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT02848274Recruiting
Looking for factors that predict outcomes in advanced skin lymphoma
This study looks at medical and disease details to find factors that can help predict how advanced mycosis fungoides or Sézary syndrome will behave. Your information may help doctors better estimate prognosis and plan care.
Duarte, CaliforniaAges Any age - NCT02982902RecruitingEarly Phase 1
T cell treatment for stubborn CMV after stem cell transplant
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
Cleveland, OhioAges 3 months+ - NCT03047369Recruiting
Myelin brain disorder research biobank for samples and data
This study collects brain-related medical information and biological samples to help researchers better understand leukodystrophies and other white-matter brain disorders. It may help future diagnosis and treatments by building a valuable “biobank” of patient data and samples.
Los Angeles, CaliforniaAges Any age - NCT06096857RecruitingPhase 2
Cardamom and topical bacteria cream for eczema
This study tests whether taking cardamom by mouth and applying a cream made from a harmless bacteria (Roseomonas) can help treat eczema (atopic dermatitis) in people age 2 and older.
Bethesda, MarylandAges 2–100 - NCT06092346Recruiting
Understanding rare purine and pyrimidine metabolism disorders
This study aims to learn more about rare disorders of purine and pyrimidine metabolism (DPPM), which can affect the brain, immune system, kidneys, and muscles. Researchers will study people with these disorders, their family members, and healthy volunteers to better understand the condition over time.
Bethesda, MarylandAges 1 month–100 years - NCT06103838RecruitingPhase 2
Fluciclovine PET/CT scan for multiple myeloma
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
Bethesda, MarylandAges 18–120 - NCT06091254RecruitingPhase 3
Comparing odronextamab to standard chemo for untreated follicular lymphoma
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Tucson, ArizonaAges 18 years+ - NCT06082037RecruitingPhase 3
Testing belumosudil for chronic lung allograft dysfunction after transplant
This trial tests an oral medication called belumosudil for people with chronic lung allograft dysfunction (CLAD) after a double lung transplant. It may help slow the decline in lung function.
Birmingham, AlabamaAges 18 years+ - NCT06087653RecruitingPhase 1/Phase 2
Continuous lenalidomide shot for multiple myeloma
This trial tests a new way to give lenalidomide (Revlimid) as a continuous shot under the skin (subcutaneous infusion) for people with multiple myeloma that has come back or not responded after at least one prior treatment. The goal is to see if this method works better and is easier to tolerate than the standard pill form.
Wilson, North CarolinaAges 18 years+ - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Scottsdale, ArizonaAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT06081439Recruiting
Immune markers and mental fatigue in Graves' disease
This study looks at whether certain immune system markers are linked to mental fatigue (feeling tired or foggy in the mind) in people with newly diagnosed Graves' disease. If you join, you'll help researchers understand how your immune system might affect your energy and thinking.
GothenburgAges 18–72 - NCT04885179Recruiting
Study of SPLIS genetics and patient experiences
This observational study and patient registry collects information from people diagnosed with SPLIS due to specific changes in the SGPL1 gene, including children and newborns. It helps researchers understand the condition better and may improve future care and research planning.
San Francisco, CaliforniaAges Any age - NCT06088277Recruiting
Texting to reduce HIV risk for dental patients
This study tests if daily text messages can help people lower their risk of getting HIV. You'll receive texts for a few months and complete surveys to see if the messages help.
Boston, MassachusettsAges 18 years+ - NCT06098430Recruiting
Quality of life in NLPHL patients
This study looks at how people with a rare type of Hodgkin lymphoma (NLPHL) feel about their health and quality of life. By filling out surveys, you can help doctors understand what really matters to patients like you.
Palo Alto, CaliforniaAges 8 years+ - NCT06093204Recruiting
Ultra-processed foods and eosinophilic esophagitis study
This study looks at how certain chemicals from ultra-processed foods (like packaged snacks and sodas) might trigger eosinophilic esophagitis, a food allergy condition. It will compare people with the disease to healthy volunteers of the same age and sex.
Naples, NaplesAges 3–65 - NCT06090864RecruitingPhase 1/Phase 2
Engineered immune cells for Hodgkin lymphoma
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
Chapel Hill, North CarolinaAges 18 years+ - NCT06103370Recruiting
HIV prevention via telemedicine and peer networks
This study tests how well a program combining telemedicine (virtual doctor visits) and peer support can help prevent HIV among people who inject drugs. You'd get trained, attend weekly group sessions, and invite a friend or partner to also take part.
Baltimore, MarylandAges 18 years+ - NCT06102330Recruiting
Helping parents decide about home breathing machines
This study helps parents like you who are deciding whether their child should have a breathing machine at home. You'll use a website or get support by phone to learn about your options and share what matters most to your family, so doctors and families can make better choices together.
Tampa, FloridaAges 18 years+ - NCT06099912Recruiting
Personalized frailty-based treatment for older adults with new multiple myeloma
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
Changchun, JilinAges 65 years+ - NCT06083922RecruitingPhase 2
CyBorD plus Daratumumab for kidney disease caused by abnormal proteins
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
Boston, MassachusettsAges 18 years+ - NCT06100237RecruitingPhase 2
Teclistamab and daratumumab for high-risk smoldering myeloma
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
Miami, FloridaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.